

This is a repository copy of Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): multicenter, early feasibility study.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/158002/

Version: Published Version

Article:

Rothman, A. orcid.org/0000-0002-7847-4500, Kiely, D., Vachiery, J.-L. et al. (17 more authors) (2020) Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): multicenter, early feasibility study. JACC: Cardiovascular Interventions, 13 (8). pp. 989-999. ISSN 1936-8798

https://doi.org/10.1016/j.jcin.2019.12.027

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



JACC: CARDIOVASCULAR INTERVENTIONS © 2020 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1)



Multicenter, Early Feasibility Study

Alexander M.K. Rothman, BMBCH, PHD,^a Jean-Luc Vachiery, MD,^b Luke S. Howard, MA, DPHL,^c Ghada W. Mikhail, MBBS, MD,^c Irene M. Lang, MD,^d Michael Jonas, MD,^e David G. Kiely, MD,^a Dalit Shav, PHD,^f Or Shabtay, BSc,^f Avital Avriel, MD,^g Gregory D. Lewis, MD,^h Erika B. Rosenzweig, MD,ⁱ Ajay J. Kirtane, MD, SM,^{i,j} Nick H. Kim, MD,^k Ehtisham Mahmud, MD,^k Vallerie V. McLaughlain, MD,¹ Stanley Chetcuti, MD,¹ Martin B. Leon, MD,^{i,j} Ori Ben-Yehuda, MD,^j Lewis J. Rubin, MD^k

ABSTRACT

OBJECTIVES The aim of this study was to investigate whether therapeutic intravascular ultrasound pulmonary artery denervation (PDN) is safe and reduces pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH) on a minimum of dual oral therapy.

BACKGROUND Early studies have suggested that PDN can reduce PVR in patients with PAH.

METHODS TROPHY1 (Treatment of Pulmonary Hypertension 1) was a multicenter, international, open-label trial undertaken at 8 specialist centers. Patients 18 to 75 years of age with PAH were eligible if taking dual oral or triple nonparenteral therapy and not responsive to acute vasodilator testing. Eligible patients underwent PDN (TIVUS System). The primary safety endpoint was procedure-related adverse events at 30 days. Secondary endpoints included procedure-related adverse events, disease worsening and death to 12 months, and efficacy endpoints that included change in pulmonary hemodynamic status, 6-min walk distance, and quality of life from baseline to 4 or 6 months. Patients were to remain on disease-specific medication for the duration of the study.

RESULTS Twenty-three patients underwent PDN, with no procedure-related serious adverse events reported. The reduction in PVR at 4- or 6-month follow-up was $94 \pm 151 \text{ dyn} \cdot \text{s} \cdot \text{cm}^{-5}$ (p = 0.001) or 17.8%, which was associated with a 42 ± 63 m (p = 0.02) increase in 6-min walk distance and a $671 \pm 1,555$ step (p = 0.04) increase in daily activity.

CONCLUSIONS In this multicenter early feasibility study, PDN with an intravascular ultrasound catheter was performed without procedure-related adverse events and was associated with a reduction in PVR and increases in 6-min walk distance and daily activity in patients with PAH on background dual or triple therapy. (J Am Coll Cardiol Intv 2020;13:989-99) © 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

From the ^aUniversity of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; ^bCliniques Universitaires de Bruxelles, Erasme Hospital, Brussels, Belgium; ^cHammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom; ^dMedical University of Vienna, Vienna, Austria; ^eKaplan Medical Center, Rehovot, Israel; ^fSoniVie, Rosh Haayin, Israel; ^gBarzilai Medical Center, Ashkelon, Israel; ^hMassachusetts General Hospital, Boston, Massachusetts; ⁱUniversity of Columbia Medical Center, NewYork-Presbyterian Hospital, New York, New York; ^jCardiovascular Research Foundation, New York, New York; ^kUniversity of California, San Diego, San Diego, California; and the ⁱUniversity of Michigan, Ann Arbor, Michigan. This work was supported by SoniVie. Dr. Rothman is supported by a Wellcome Trust grant (206632/Z/17/Z). Drs. Rothman, Vachiery, Jonas, Leon, Ben-Yehuda, and Rubin have consulted for SoniVie. Dr. Rothman has received research support from Actelion, Medtronic, Novartis, and Abbott. Dr. Vachiery has received institutional support from Actelion, GSG Arena Pharmaceuticals, Bial Portela, Merck Sharp & Dohme, United Therapeutics, Novartis, and Respira Therapeutics. Dr. Lang has received fees from Actelion, AOPOrphan, Merck Sharp & Dohme, Ferrer, Medtronic, and United Therapeutics. Dr. Kiely has received fees and research support from Actelion and GlaxoSmithKline; and has received fees from Bayer and Merck Sharp & Dohme. Dr. Lewis has received research support from Novartis, Actelion, Ironwood, Cytokinetics, Applied Therapeutics, and Bayer. Dr. Lewis has received research support from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, Cathworks, Siemens, Philips, and ReCore

ABBREVIATIONS AND ACRONYMS

PAH = pulmonary arterial hypertension

PDN = pulmonary artery denervation

PVR = pulmonary vascular resistance

atients with pulmonary arterial hypertension (PAH) manifest signs of sympathetic overdrive (1) that are associated with poor outcomes (2). The lungs are a major source of catecholamines and both release and metabolize >40% of circulating levels (3). It is unknown whether activation of the sympathetic nervous system is a secondary phenomenon or whether it may play an exacerbating and/or pathogenic role in the progression of disease. In experimental models of pulmonary hypertension, therapies that target the sympathetic (4,5) and renin-angiotensin-aldosterone (6) systems reduce small-vessel remodeling and improve hemodynamic status. However, in patients with PAH, the few studies undertaken thus far have demonstrated modulation of both pulmonary and systemic hemodynamic status, with no evidence of clinical benefit (7-9). Furthermore, beta-adrenergic blockade may produce deterioration in patients with PAH resulting from the systemic hemodynamic effects (hypotension, reduced heart rate, and cardiac output).

SEE PAGE 1000

Catheter-based renal denervation in patients with systemic hypertension reduces blood pressure (10-12). Such technologies offer the opportunity to modulate sympathetic activity through targeted denervation of the pulmonary vasculature, potentially avoiding the adverse effects of systemically active therapies. Nerves surrounding the pulmonary vasculature are present to a depth of 4 mm in large animals (13,14) and 10 mm in human samples (15). In patients with PAH, the application of radiofrequency energy to a specific location at the bifurcation is reported to provide an acute improvement in hemodynamic status that persists to 3 months despite the withdrawal of disease-specific therapy (16). Current guidelines indicate that patients with PAH and high-risk indicators should be treated with 2 diseasespecific therapies (17). As such, the effect of pulmonary artery denervation (PDN) in patients on best medical therapy is unknown, as is the feasibility of ultrasound energy delivery for PDN.

The TIVUS System (SoniVie, Rosh Haayin, Israel) is a percutaneous, noncontact catheter that provides a fenestrated ring of thermal effect to a depth of 10 mm, which is the expected location of the efferent and afferent autonomic nerves in the pulmonary artery adventitia (15). We designed this preliminary study to investigate for the first time the feasibility of therapeutic intravascular ultrasound PDN, to monitor early safety, and to determine whether the procedure would lower pulmonary vascular resistance (PVR) in patients with PAH established on a minimum of dual oral therapy.

METHODS


STUDY DESIGN AND PARTICIPANTS. TROPHY1 (Treatment of Pulmonary Hypertension 1) was a multicenter, open-label, early feasibility study. Participants were recruited from 5 hospitals in Europe and Israel and 3 in the United States. The study was undertaken in accordance with the Declaration of Helsinki and was approved by local ethics committees or Institutional Review Boards. All participants provided written informed consent. Briefly, eligible patients were men or women 18 to 75 years of age with PAH that did not respond to vasodilator testing, on a minimum of dual oral disease-specific therapy (17), with estimated glomerular filtration rate \geq 30 ml/min/1.73 m².

PROCEDURES. After qualifying hemodynamic evaluation and pulmonary angiography, patients underwent immediate therapeutic intravascular ultrasound PDN (TIVUS System). A maximum of 18 activations were delivered to nonoverlapping segments of the main (n = 8), right (n = 8), and left (n = 2) pulmonary arteries. The number of activations and distance from the pulmonary artery bifurcation was limited on the left by the recurrent laryngeal nerve (15). Continuous monitoring of energy output, vessel wall distance, and temperature was used to optimize each activation, with automated safety cut-outs. Patients were sedated and received pain-controlling medication at the discretion of the responsible physician. The target activated coagulation time of >250 s was achieved with intravenous heparin to prevent coagulum buildup on the ultrasound probe.

Post-procedural follow-up was at 1 month, 4 or 6 months (Europe and Israel, 4 months; United States, 6 months; mean 4.8 \pm 1.3 months), 8 months, and 12 months. Systemic blood pressure and heart

Manuscript received May 9, 2019; revised manuscript received November 25, 2019, accepted December 17, 2019.

Medical. Dr. McLaughlain has received research support and fees from Acceleron, Actelion, and Bayer; has received research support from Eiger BioPharmaceuticals and Reta Pharmaceuticals; and has received fees from Arena, Caremark, Corsair Pharma, Merck, and United Therapeutics. Drs. Shav and Shabtay are employees of SoniVie. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.



rate, adverse events, 6-min walk distance, and medications were recorded and laboratory assessments undertaken at each visit. Right heart catheterization was performed at baseline and 4- or 6-month and 12month follow-up in the supine position, with pulmonary pressure and flow measurements repeated in triplicate. Magnetic resonance imaging or computed tomography was performed at 1 and 6 or 12 months. Wrist-based activity monitoring was undertaken for 14 days (ActiGraph GT9X Link, ActiGraph, Pensacola, Florida) prior to baseline, 4- or 6-month, 8-month, and 12-month visits. **OUTCOMES.** The primary endpoint was procedurerelated adverse events at 30 days (pulmonary artery perforation, dissection, aneurysm, or stenosis; hemoptysis; and disease- or procedure-related death). Secondary endpoints included PAH worsening and death to 12 months and change from baseline to 4- or 6-month follow-up in PVR, mean pulmonary artery pressure, right atrial pressure, 6-min walk distance, quality of life (emPHasis-10), N-terminal pro-brain natriuretic peptide, disease-specific medication, and actigraphy. The time-to-event endpoint was a composite of death, disease-related hospitalization,

TABLE 1 Baseline Characteristics of Patients	Enrolled (N = 23)
Age, yrs	60.0 ± 11.4
Female	18 (78)
Race	
Caucasian	19 (83)
Black	1 (4)
Hispanic	2 (9)
Middle East	1 (4)
Time from diagnosis, yrs	$\textbf{6.1} \pm \textbf{5.7}$
Type of PAH	
Associated with connective tissue disease	12 (52)
Associated with drug use	3 (13)
Idiopathic	8 (35)
WHO functional class III	23 (100)
Values are mean \pm SD or n (%).	

PAH = pulmonary arterial hypertension; WHO = World Health Organization.

initiation of parenteral prostanoid therapy, lung transplantation, or atrial septostomy, whichever occurred first, to 12 months (18). Risk assessment was undertaken using the French invasive score with lowrisk criteria defined as World Health Organization functional class I or II, 6-min walk distance >440 m, right atrial pressure <8 mm Hg, and cardiac index \geq 2.5 l/min/m² (19). An independent data and safety monitoring board reviewed all potential procedure-related serious adverse events and adverse events.

BLINDED DATA ANALYSIS. Hemodynamic data were analyzed blinded to participant and time point by an independent core laboratory (Cardiovascular Research Foundation, New York, New York).

TABLE 2Medical Therapy of Patients at Baseline and 4- or6-Month Follow-Up (N = 20)					
Disease-Specific Therapy	Baseline	4 or 6 Months			
ERA/PDE5 inhibitor	10 (50)	10 (50)			
ERA/sGC	4 (20)	4 (20)			
ERA/PDE5 inhibitor/inhaled prostacyclin	3 (15)	3 (15)			
ERA/sGC/inhaled prostacyclin	2 (10)	2 (10)			
ERA/sGC/oral IP agonist	1 (5)	1 (5)			
Diuretic agents					
None	3 (15)	3 (15)			
Loop	7 (35)	6 (30)			
Loop/aldosterone antagonist	7 (35)	8 (40)			
Loop/aldosterone antagonist/thiazide	3 (15)	3 (15)			
Values are n (%).					
ERA = endothelin receptor antago PDE5 = phosphodiesterase type 5; sGC = soluble		 prostacyclin; vclase. 			

STATISTICAL ANALYSIS. Statistical analyses were performed using 1-way analysis of variance, the Wilcoxon matched-pairs signed rank test, Student's paired *t*-test, and the chi-square test as appropriate in accordance with the pre-specified statistical analysis plan. Reported adverse events are of all patients enrolled, but patients who did not undergo follow-up right heart catheterization were excluded in the reporting of hemodynamic and functional endpoints (**Figure 1**). Expected survival was modeled from 6-min walk distance, sex, and cardiac output using the French registry equation (20).

The study is registered at ClinicalTrials.gov (NCT02516722, NCT02835950).

FUNDING. The study was funded by SoniVie. The advisory committee and sponsor designed the study. Independent data collection and monitoring were undertaken by site-specific contract research organizations. Statistical analyses were performed by the Cardiovascular Research Foundation. All authors had access to data and were responsible for the decision to submit.

RESULTS

Between March 2015 and April 2018, 24 patients with PAH on a minimum of dual oral therapy were enrolled in TROPHY1. After qualifying right heart catheterization, 23 patients underwent PDN.

Baseline characteristics are shown in **Table 1**. The mean age was 60.0 ± 11.4 years, 18 patients (78%) were women, and 19 (83%) were Caucasian. At the time of enrollment, all patients were receiving dual oral therapy, and 7 (30%) were also receiving an inhaled prostanoid or oral prostacyclin agonist (**Table 2**).

Patients received an average of 10.0 (minimum 7, maximum 16) ultrasound activations, with 4.5 (range: 2 to 7), 1.9 (range: 1 to 2), and 4.0 (range: 1 to 8) in the right, left, and main pulmonary arteries, respectively, with all patients receiving the pre-specified minimum (2 right, 1 left, and 2 main). The duration of the denervation procedure was 32.0 ± 9.8 min, with a mean fluoroscopy time of 8.1 ± 5.4 min.

There were no procedure-related serious adverse events. Serious adverse events and adverse events are shown in **Table 3**. No patients reported procedurerelated pain lasting longer than 2 days, and no perforation, dissection, aneurysm, or stenosis was identified by pulmonary angiography post-procedure or magnetic resonance imaging or computed tomography at 1 and 12 months. There was no acute reduction in mean pulmonary artery pressure $(+0.7 \pm 10.0 \text{ mm Hg}; \text{p} = \text{NS})$, and no change in estimated glomerular filtration rate was apparent at 1 month (6.1 \pm 27.0 ml/min/1.73 m²; p = NS). Three subjects did not undergo follow-up right heart catheterization and were not included in efficacy analysis: 1 transitioned to intravenous prostanoid, 1 died (unrelated to the procedure), and 1 was nonadherent to therapy (Figure 1). Survival at 4 or 6 and 12 months was 96%. The French registry equation was used to estimate expected survival on the basis of patient data at the point of study entry; expected survival was 93% and 87% at 6 and 12 months, respectively (20). Disease-specific therapy was unchanged between baseline and 4- or 6-month follow-up in patients included in the efficacy analysis (Table 2). Diuretic therapy was consistent between time points (Table 2): furosemide equivalent 54 mg/day (range: 0 to 160 mg/day) versus 59 mg/day (range: 0 to 160 mg/day), aldosterone antagonist 15 mg/day (range: 0 to 50 mg/day) versus 16.25 mg/day (range: 0 to 50 mg/day), and thiazide 0.5 mg/day (range: 0 to 5 mg/day) versus 0.5 mg/day (range: 0 to 5 mg/day).

At 4- or 6-month follow-up, hemodynamic and functional endpoints improved: PVR was reduced by 94 \pm 151 dyn·s·cm^{-5} (p = 0.001), or 17.8%, and 6-min walk distance increased by 42 \pm 63 m (p = 0.02) (Figures 2 to 4, Central Illustration, Table 4). Improvements in mean pulmonary artery pressure $(-5.1 \pm 7.4 \text{ mm Hg; p} < 0.01)$, right atrial pressure $(-2.4 \pm 3.5 \text{ mm Hg}; p = 0.01)$, and pulmonary arterial compliance (+0.39 \pm 0.83 ml/mm Hg; p < 0.01) were also observed (Figure 2, Central Illustration, Table 4). Reductions from baseline PVR of >10% were observed in 14 patients (70%), and of those, 8 (40%) had reductions of >20% (Figure 3). At 4 or 6 months, daily activity was increased by $671 \pm 1,555$ steps (p = 0.04), but no alteration was identified in cardiac output $(+0.3 \pm 0.9 \text{ l/min}; \text{ p} = \text{NS})$, stroke volume index (+4.85 \pm 11.5 ml/min/m²; p = 0.09), quality of life (emPHasis-10 score -5.1 ± 12.4 ; p = 0.20), N-terminal pro-brain natriuretic peptide ($-263.5 \pm 1,120 \text{ pg/ml};$ p = 0.2), systemic blood pressure (+4.8 \pm 24.4 mm Hg; p = NS), and heart rate (+0.05 \pm 8.2 beats/min; p = NS) (Figures 2 and 4, Supplemental Figure 1, Table 4). Hemodynamic and functional improvements were reflected in an increased number of European Society of Cardiology low-risk indicators achieved at 4- or 6-month follow-up (European Society of Cardiology/French invasive risk score 0.4 \pm 0.6; p < 0.001) (Figure 4, Central Illustration). Following PDN, clinical worsening events occurred in 6 patients, which were distributed throughout the follow-up period (Figure 4).

TABLE 3 Serious Adverse Events and Adverse Events (All Patients Enrolled, N = 23)


Event	n	Description
Serious adverse events		
PAH hospitalization	11	Right ventricular failure/volume overload, syncope, initiation of IV prostacyclin
Non-PAH hospitalization	3	Digoxin overdose, vasovagal episode, exacerbation of lung disease
Death	1	Cardiac arrest
Adverse events		
Anemia	2	
Cardiac/PAH	32	Edema, chest pain, ECG changes, palpitations, breathlessness, PAH progression/worsening
Infection	16	Urinary, respiratory, gastroenterological, dermatological, dental
Pain	10	Pain during procedure, neck pain
Procedure related	7	Bleeding, hematoma, bruising, low saturation
Renal impairment	3	
ECG = electrocardiographic: IV = i	ntraveno	pus: PAH = pulmonary arterial hypertension.

DISCUSSION


This is the first study to examine the feasibility of therapeutic intravascular ultrasound PDN and describe early safety and clinical outcome indicators. Following qualifying right heart catheterization, patients with PAH on a minimum of dual oral therapy underwent immediate PDN. No procedure-related serious adverse events were reported, and pulmonary hemodynamic status, 6-min walk distance, and daily activity improved at 4 or 6 months.


Patients were recruited from specialist pulmonary hypertension centers, and the female predominance, hemodynamic severity, and background therapy are similar to those of large registries (21,22). The mean age of 60 years, lengthy diagnosis-to-enrollment duration, large number of patients on triple therapy, and high proportion of connective tissue diseaseassociated PAH also suggest that patients enrolled were those established on guideline-directed therapy with limited options for therapeutic escalation or transplantation.

Ultrasound PDN was undertaken with no procedure-related serious adverse events reported. Of the 15 severe adverse events, 11 were diseaserelated deterioration. At 12-month follow-up, clinical worsening events had occurred in 6 of the 23 patients enrolled, a number typical for patients in World Health Organization functional class III or IV (23,24). As such, procedural feasibility and early safety appear acceptable. Disease-specific and diuretic therapy were maintained from baseline to follow-up. At 4 or 6 months following PDN, a




±95% CI; mean diastolic pulmonary artery pressure: lower, –95% CI). (B) Pulmonary vascular resistance (PVR). (C) Right atrial pressure (RAP). (D) Cardiac output (CO). (E) Pulmonary capillary wedge pressure (PCWP). (F) Systolic blood pressure (SBP). (G) Heart rate. (H) Pulmonary arterial compliance (PCa). (I) Stroke volume index (SVI). n = 20, mean \pm 95% CI, Wilcoxon matched-pairs signed rank test or Student's paired t-test as appropriate.





94 dyn·s·cm⁻⁵ reduction in PVR was observed, 6-min walk distance was increased by 42 m, and systemic blood pressure and heart rate were not altered. In keeping with the observed reduction in PVR, both right atrial pressure and pulmonary artery compliance were improved (22). Although not statistically significant, stroke volume index increased to a level above the optimal absolute cutoff threshold associated with mortality or transplantation (38 ml/min/m²) (22). In comparison with prior reports of PDN in patients with PAH (PADN-1 [First-in-Man Pulmonary Artery Denervation for Treatment of Pulmonary Artery Hypertension]) (16), patients enrolled in TRO-PHY1 were older, with a longer time from diagnosis and a high predominance of connective tissue disease, and were all established on guideline-directed therapy. Consistent with PADN-1 (16), PDN improved PVR in a manner driven primarily by a reduction in pulmonary artery pressure. However, in TROPHY1, no on-table reduction in pulmonary artery pressure was apparent, and the magnitude of changes was less marked. The observed reduction in PVR and increase in 6-min walk distance achieved at 4 or 6 months in TROPHY1 are in line with hemodynamic



(A) Pulmonary artery pressure (mean systolic pulmonary artery pressure: **upper**, +95% confidence interval [CI]; mean of mean pulmonary artery pressure: **white circles**, \pm 95% CI; mean diastolic pulmonary artery pressure: **lower**, -95% CI). (B) Pulmonary vascular resistance (PVR). (C) Right atrial pressure (RAP). (D) Distance walked on 6-min walk test (6MWT). (E) European Society of Cardiology risk score. n = 20, mean \pm 95% CI, 1-way analysis of variance, Student's paired *t*-test, and chisquare test as appropriate. outcomes of approved drug therapies and compare favorably with a minimally important clinical difference in 6-min walk distance of 33 m (25). The observed increase in daily activity and improved clinical risk score provide further indication of potential benefit on a background of guideline-directed medical therapy.

Markers of neurohormonal activity are increased in patients with PAH and are associated with adverse clinical events (1,2). The pulmonary vasculature is highly innervated, releasing and metabolizing >40% of circulating catecholamines (3). The pulmonary (nerve) plexus is predominantly sympathetic and is innervated by fibers from the spinal ganglions (sympathetic) and vagus nerve (parasympathetic) (15). Baroreceptor structures have been described at the pulmonary artery bifurcation (26), and balloon distention of the main pulmonary artery increases pulmonary artery pressure and PVR (27). These acute changes are abrogated by surgical denervation and chemical sympathectomy implicating sympathetic nerves in the reflex (27). Furthermore, sympathetic inhibition, through cervical ganglion block, reduces pulmonary artery pressure in the context of acute pulmonary embolism (28). In experimental models, denervation of the pulmonary artery induces persistent structural and functional changes within associated nerves and improves hemodynamic changes driven by balloon distention (29), vasoconstriction (13,15), and small-vessel remodeling (14). The elevated PVR apparent in patients with PAH is driven by small-vessel remodeling but also leads to increased pulmonary artery pressure. The present study demonstrates improvements in pulmonary vascular hemodynamic status and functional capacity 4 or 6 months following PDN. In contrast to prior reports of radiofrequency PDN, no acute reduction in pulmonary artery pressure was observed with ultrasound PDN in this study, suggesting a potential remodeling effect.

The health-economic cost of PAH-specific therapy and clinical deterioration is high (30); dual oral therapy is priced at \$30,000 to \$50,000 per year per patient and triple therapy at \$50,000 to \$160,000 per patient per year (31,32). As such, a single, or repeatedinterval, catheterization laboratory-based procedure may provide an alternative to therapeutic escalation or an addition to combination therapy.

STUDY STRENGTHS AND LIMITATIONS. The study was open label, with no placebo arm. Patients and responsible physicians were not blinded, and the potential effect of placebo cannot be quantified.

	Baseline	4 or 6 Months	p Valu
Right atrial pressure (mm Hg)	10.7 (8.1-13.3)	8.3 (6.1-10.5)	0.008
Pulmonary artery pressure (mm Hg) Systolic Mean Diastolic	80.7 (68.8-92.5) 49.3 (42.5-56.1) 32.1 (27.3-36.8)	74.3 (63.1-85.4) 44.2 (37.4-51.0) 27.7 (22.3-33.1)	0.02 0.00 0.00
Pulmonary arterial wedge pressure (mm Hg)	13.4 (11.2-15.6)	12.9 (10.6-15.3)	0.63
Cardiac output (l/min)	4.9 (4.3-5.6)	5.2 (4.4-6.1)	0.41
Pulmonary vascular resistance (dyn·s·cm ⁻⁵)	670 (479-861)	576 (373-779)	0.00
Systemic blood pressure (mm Hg) Systolic Diastolic	120 (113.0-126.9) 75.4 (69.7-81.1)	124.1 (112.4-135.7) 75.7 (69.5-81.9)	0.72 0.74
Heart rate (beats/min)	78.4 (73.7-83.2)	78.1 (72.4-83.8)	0.87

Values are mean (95% confidence interval).

Patients were recruited from specialist centers at which serial walk testing was part of routine care, thereby reducing potential training and learning effects. To minimize potential bias, hemodynamic studies were assessed by an independent core laboratory, blinded to subject and sequence, and data were analyzed by an independent statistician in accordance with the pre-specified analysis plan. Additionally, for this procedure, there is no immediate feedback to the operator to indicate successful denervation.

CONCLUSIONS

Intravascular ultrasound PDN was feasible, reduced PVR, and increased 6-min walk distance and daily activity in patients with PAH treated with dual oral or triple therapy. Further studies are required to evaluate the efficacy, durability, safety, and long-term clinical impact of PDN in patients with pulmonary hypertension of various forms.

ACKNOWLEDGMENTS The authors acknowledge the contribution of study participants. Dr. Rothman acknowledges the support of the National Institute for Health Research Sheffield Clinical Research Facility, Dr. Robin Condliffe, Prof. Julian Gunn, Prof. Tim Chico, and Dr. Roger Thompson.

ADDRESS FOR CORRESPONDENCE: Dr. Alexander Rothman, Department of Infection, Immunity and Cardiovascular Disease, The Medical School, The University of Sheffield, Beech Hill Road, Sheffield S10 2RX, United Kingdom. E-mail: a.rothman@ sheffield.ac.uk.

PERSPECTIVES

WHAT IS KNOWN? Early studies have suggested that PDN reduces PVR in patients with PAH.

WHAT IS NEW? In this multicenter early feasibility study, ultrasound PDN was performed without procedure-related adverse events and was associated with a reduction PVR and increases in 6-min walk distance and daily activity in patients with PAH on a minimum of dual oral therapy.

WHAT IS NEXT? Further studies are required to evaluate the efficacy, durability, safety, and long-term clinical impact of PDN in patients with pulmonary hypertension of various forms.

REFERENCES

1. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, Van De Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;110:1308–12.

 Ciarka A, Doan V, Velez-Roa S, Naeije R, Van De Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181: 1269–75.

3. Esler M, Willett I, Leonard P, et al. Plasma noradrenaline kinetics in humans. J Auton Nerv Syst 1984;11:125-44.

4. De Man FS, Handoko ML, Van Ballegoij JJM, et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Hear Fail 2012;5:97–105.

5. Perros F, Ranchoux B, Izikki M, et al. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. J Am Coll Cardiol 2015; 65:668–80.

6. De Man FS, Handoko ML, Guignabert C, Bogaard HJ, Vonk-Noordegraaf A. Neurohormonal axis in patients with pulmonary arterial hypertension: friend or foe? Am J Respir Crit Care Med 2013;187:14–9.

7. Thenappan T, Roy SS, Duval S, Glassner-Kolmin C, Gomberg-Maitland M. β -Blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis. Circ Hear Fail 2014;7: 903-10.

8. Bandyopadhyay D, Bajaj NS, Zein J, Minai OA, Dweik RA. Outcomes of β -blocker use in pulmonary arterial hypertension: a propensity-matched analysis. Eur Respir J 2015;46:750–60.

9. Marcus JT, van de Veerdonk MC, Bogaard H-J, et al. Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. Eur Respir J 2016;48:787-96.

10. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-ofconcept trial. Lancet 2017;390:2160-70.

11. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018;391: 2335-45.

12. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391:2346-55.

13. Rothman AMK, Arnold ND, Chang W, et al. Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension. Circ Cardiovasc Interv 2015;8:e002569.

14. Zhou L, Zhang J, Jiang X-M, et al. Pulmonary artery denervation attenuates pulmonary arterial remodeling in dogs with pulmonary arterial hypertension induced by dehydrogenized mono-crotaline. J Am Coll Cardiol Intv 2015;8:2013-23.

15. Rothman AMK, Jonas M, Castel D, et al. Pulmonary artery denervation using catheter-based ultrasonic energy. EuroIntervention 2019;15: 722-30.

16. Chen SL, Zhang FF, Xu J, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (First-in-Man Pulmonary Artery Denervation for Treatment of Pulmonary Hypertension). J Am Coll Cardiol 2013;62: 1092–100.

17. Galie N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endor. Eur Heart J 2015;37:67-119.

18. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in

pulmonary arterial hypertension. N Engl J Med 2013;369:809-18.

19. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017;50:1–10.

20. Sitbon O, Benza RL, Badesch DB, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J 2015;46:152-64.

21. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Center. Eur Respir J 2012;39:945–55.

22. Weatherald J, Boucly A, Chemla D, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation 2018;137: 693-704.

23. Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial. J Am Coll Cardiol HF 2015;3:1-8.

24. McLaughlin VV, Hoeper MM, Channick RN, et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol 2018;71:752-63.

25. Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186: 428-33.

26. Osorio J, Russek M. Reflex changes on the pulmonary and systemic pressures elicited by stimulation of baroreceptors in the pulmonary artery. Circ Res 1962;10:664-7.

27. Juratsch C, Jengo J, Castagna J, Laks M. Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest 1980;77:525-30.

28. Faxon H, Flynn JH, Anderson RM. Stellate block as an adjunct to the treatment of pulmonary embolism. N Engl J Med 1951;244:586–90.

29. Chen SL, Zhang YJ, Zhou L, et al. Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. EuroIntervention 2013;9: 269-76.

30. Dufour R, Pruett J, Hu N, et al. Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class. J Med Econ 2017;20:1178-86.

31. Macitentan (Opsumit): for long-term treatment of pulmonary arterial hypertension. Common Drug Review. Canadian Agency for Drugs and Technologies in Health; 2015. Available at: https://www. ncbi.nlm.nih.gov/books/NBK349255/. Accessed December 26, 2019.

32. National Health Service. Commissioning Policy: Targeted Therapies for Use in Pulmonary Hypertension in Adults. Available at: https://www. england.nhs.uk/wp-content/uploads/2018/07/ Targeted-therapies-for-use-in-pulmonaryhypertension-in-adults.pdf. Accessed December 26, 2019.

KEY WORDS denervation, pulmonary hypertension, ultrasound

APPENDIX For a supplemental figure, please see the online version of this paper.